Evaluating Glofitamab Alone in Chinese Adults Aged 18 to 80 With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Two or More Previous Treatments

What this Trial Is About

Researchers are evaluating glofitamab as a single treatment in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma DLBCL who have not responded to at least two previous systemic therapies. The study aims to assess the safety and effectiveness of this drug in managing this type of lymphoma. Participants will receive glofitamab at standard doses as the only treatment during the study. This observational study monitors patients over time without comparing to a placebo or other therapies. The focus is on how well the drug works and its safety in this specific patient group. During the study, researchers will follow patients for at least one year to measure progression-free survival. Additional outcomes include overall survival over two years, complete response rates at 6, 18, and 36 weeks, overall response rates at the same intervals, duration of response over two years, and adverse events over two years. Patients will undergo assessments to track disease status and treatment side effects throughout the study period.

Glofitamab in Chinese Patients With R/R DLBCL